Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYUREA versus PYQUVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYUREA versus PYQUVI.
HYDROXYUREA vs PYQUVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits ribonucleotide reductase, leading to decreased DNA synthesis and cell cycle arrest in S phase; also increases fetal hemoglobin production by inducing nitric oxide and altering erythroid progenitor signaling.
Pyquvi (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-2α, promoting erythropoietin production and iron mobilization, thereby stimulating erythropoiesis.
Oral: 15-20 mg/kg once daily (rounded to nearest 500 mg) for myeloproliferative disorders (e.g., essential thrombocythemia); 80 mg/kg every 3 days (as 35 mg/kg single dose) for sickle cell disease.
400 mg orally once daily with food, continued until disease progression or unacceptable toxicity.
None Documented
None Documented
Clinical Note
moderateHydroxyurea + Digoxin
"Hydroxyurea may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateHydroxyurea + Digitoxin
"Hydroxyurea may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateHydroxyurea + Deslanoside
"Hydroxyurea may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateHydroxyurea + Acetyldigitoxin
"Hydroxyurea may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 3.5–4.5 hours; clinical context: hematologic effects persist for 24-48 hours due to irreversible inhibition of ribonucleotide reductase.
The terminal elimination half-life is approximately 50 hours (range 40–60 hours), supporting once-daily dosing. Steady-state is achieved within 2–3 weeks of continuous dosing.
Renal: approximately 80% (30-60% unchanged; remainder as metabolites). Fecal: <10%.
Primarily hepatic metabolism via CYP3A4 and UGT1A9, with less than 5% of the dose excreted unchanged in urine. Fecal excretion accounts for approximately 70% of total clearance, primarily as metabolites.
Category A/B
Category C
Antimetabolite
Antimetabolite